Trial of Cannabidiol-derived EHP-101 for Relapsing MS Enrolling Soon

Trial of Cannabidiol-derived EHP-101 for Relapsing MS Enrolling Soon

316210

Trial of Cannabidiol-derived EHP-101 for Relapsing MS Enrolling Soon

Emerald Health Pharmaceuticals will soon begin enrollment in a Phase 2a clinical trial investigating its cannabidiol-derived therapy EHP-101 in relapsing forms of multiple sclerosis (MS). The trial (NCT04909502) aims to recruit 50 patients, ages 18-55, with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS). It follows the clearance of the company’s investigational new drug application by the U.S. Food and Drug Administration (FDA). Enrollment is expected to take place at about 30 locations in…

You must be logged in to read/download the full post.